Pandemic Perspectives: US FDA, NIH Tried To Be Flexible To Keep Rare Disease Trials Going

 
• By Derrick Gingery
  
government subsidy poverty compensation during covid-19 corona pandemic hand charity help economy crisis
NCATS Director Chris Austin said rare disease clinical trials will require rebuilding after the pandemic. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D